Advocates’ Primer on Injectable Cabotegravir for PrEP: Trials, Approvals, Rollout and More

Results from two large-scale efficacy trials found that injectable cabotegravir (CAB-LA), given every two months, was effective as a form of pre-exposure prophylaxis (PrEP) in preventing HIV in gay men and other men who have sex with men, transgender women who have sex with men, and cisgender women. CAB-LA was developed by ViiV Healthcare and is currently used in HIV treatment. It was approved by the US Food and Drug Administration (FDA) as the first form of injectable PrEP in December 2021. This document focuses on CAB-LA for prevention, outlining what’s known and what’s next for this emerging biomedical HIV prevention strategy.

Tracking and Translating the Field